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Despite many advances in surgical repair during the past 6 decades, the majority of TOF patients continue to experience residual hemodynamic and electrophysiological abnormalities. 5, 6 To effectively relieve the obstructed right ventricular outflow tract (RVOT), the surgeon must often disrupt the integrity of the pulmonary valve, which results in pulmonary regurgitation. The ensuing chronic right ventricular (RV) volume overload and akinesis or dyskinesis of the RVOT wall, along with conduction delay from the nearly universal right bundle-branch block, initiate a cascade of pathophysiological abnormalities that lead to RV dilatation and ultimately dysfunction. 7 Left ventricular dysfunction, arrhythmias, exercise intolerance, heart failure symptoms, and death may follow. 8 Residual intracardiac shunts, tricuspid regurgitation, RVOT or pulmonary artery stenosis, impaired diastolic properties, atrial enlargement, RV hypertension, intraventricular and interventricular dyssynchrony, and diffuse myocardial fibrosis are some of the factors that might accelerate the adverse cardiac remodeling and lead to worse clinical outcomes. Indeed, the adverse remodeling that leads to electromechanical cardiomyopathy manifests in increasing rates of morbidity and mortality beginning during the third decade of life. 9 Pulmonary valve replacement (PVR) is increasingly used to treat the chronic volume overload from pulmonary regurgitation. The procedure can be performed by a transcatheter technique or surgically, using one of the many available bioprosthetic valves. The procedural mortality is low, usually <1%, but not negligible. 7 Importantly, the functional integrity of all available bioprosthetic valves deteriorates over time, typically requiring repeat valve replacement within 10 years. The early results of PVR have been well described by several groups, painting a consistent picture characterized by resolution or marked reduction of pulmonary regurgitation, 30% to 40% reduction in RV end-diastolic and end-systolic volumes, unchanged RV ejection fraction, slightly increased left ventricular size with unchanged ejection fraction, decrease in RV systolic pressure in those with preprocedural RVOT obstruction, and consistent improvement in New York Heart Association functional class without a clear change in objective exercise parameters or arrhythmia burden. [10] [11] [12] [13] However, despite numerous investigations on timing, indications, techniques, and results of PVR, large gaps in knowledge persist on how best to manage these patients. To date, it remains unknown whether PVR reduces arrhythmia burden or improves survival in this population.
In this issue of Circulation, Frigiola et al 14 describe the outcomes of 1085 consecutive patients with TOF managed at the Great Ormond Street Hospital for Children from 1964 to 2009. In addition to confirming that the mortality rate in this population is 4-fold higher than that of the general population and that the burden of morbidity is substantial, the investigators shed light on a long-neglected segment of this population, those with good late clinical outcomes. The study adds an important piece to the puzzle by characterizing the cardiac phenotype of patients defined by the authors as having "good outcomes": those who reached 35 years of age without PVR, were asymptomatic, and had normal exercise tolerance. From a sample of 50 randomly selected patients without PVR who were invited to undergo detailed evaluation by echocardiography, cardiovascular magnetic resonance, and exercise testing, 14 fulfilled the above criteria for good late outcomes. Not surprisingly, these patients had a nearly normal right-sided heart structure and function, including at most mild RVOT obstruction, normal pulmonary valve annulus diameter, no more than mild to moderate pulmonary regurgitation, high-normal or minimally dilated RV, no RVOT aneurysm, and normal RV systolic function. The authors speculate that patients with this cardiac phenotype may not require additional interventions such as PVR and, hence, their primary repair can be considered "definitive."
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These results and inferences must be viewed cautiously. The cohort studied by Frigiola et al 14 comprises only patients with "simple" TOF, that is, those with patent RVOT. Patients with more complex forms such as those with pulmonary atresia and other anatomic variants or associated anomalies were excluded. Therefore, the burden of residual disease and excess mortality reported in their article depicts a best-case scenario, with higher rates of morbidity and mortality expected when high-risk groups are included. Furthermore, among the small random sample of "ideal" TOF patients who were invited for further evaluation, we do not know how many declined participation and whether those who underwent further testing represent the broader cohort of patients who are asymptomatic and did not require cardiac interventions during follow-up. Moreover, we do not know whether these patients are at risk for developing late cardiac complications such as atrial flutter/ fibrillation, ventricular tachycardia, or ventricular dysfunction. It is therefore prudent to continue to view repaired TOF as a lifelong disease that requires careful monitoring.
Despite these limitations, the study by Frigiola et al 14 provides useful information that highlights both ends of the disease spectrum and stimulates the ongoing discussion on timing and indications for PVR. Their findings confirm that a substantial proportion of adolescents and adults with repaired TOF receive PVR and that the frequency of the procedure increases as patient age rises. Notably, even among the small selected group of patients free of PVR, fewer than one third fulfilled the authors' criteria for good outcome. This raises the question of whether the remaining patients should have undergone earlier PVR and whether such a management strategy would have resulted in better outcomes. The authors correctly note the lack of consensus regarding optimal timing of PVR and comment that their study does not directly address this question; however, coupled with the observation that PVR is the most frequently performed surgical procedure in adults with congenital heart disease in the United Kingdom, their findings underscore the importance of fine-tuning the indications for PVR in this population. Despite the lack of consensus and the many persisting gaps in knowledge, the question of when to recommend PVR is a dilemma that confronts clinicians with increasing frequency. The Table provides a set of possible recommendations based on the author's interpretation of the current literature. These recommendations, which do not represent the opinion of any institution or professional society, are based on the available evidence gleaned from studies that analyzed pre-PVR markers of post-PVR normalization of ventricular size or function. Little or no information is currently available to inform us about ventricular performance late after PVR, pre-PVR risk factors for post-PVR arrhythmias, exercise intolerance, or mortality. Furthermore, we have no information on how to apply pre-PVR risk factors to different anatomic or surgical phenotypes. We also do not know whether therapeutic interventions designed to modify these risk factors will, in fact, translate into a clinical benefit. With these limitations in mind, the guidelines outlined in the Table are meant to serve as a starting point for a discussion within our field and as a stimulus for future investigations designed to shed new light on areas where data are lacking. [15] [16] [17] [18] [19] [20] The study by Frigiola et al 14 raises intriguing questions about our ability to identify patients with good outcomes late after TOF repair and, conversely, those at risk of poor outcomes. Simultaneously, though, the authors illustrate that even in a center with a large patient volume, our current ability to prognosticate remains poor, as highlighted by the 2 f. QRS duration >160 ms 11 g. Sustained tachyarrhythmia related to right-sided heart volume load 6 h. Other hemodynamically significant abnormalities:
• RVOT obstruction with RV systolic pressure ≥0.7 systemic
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• Severe branch pulmonary artery stenosis (<30% flow to affected lung) not amenable to transcatheter therapy
• Greater than or equal to moderate tricuspid regurgitation
• Left-to-right shunt from residual atrial or ventricular septal defects with pulmonary-to-systemic flow ratio ≥1.5
• 
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patients who were included in the good outcome group only to require subsequent PVR. Furthermore, as illustrated above, many controversies about optimal management of this growing population remain contentious. Thus, further progress in resolving these disagreements will only be achieved through large multicenter collaborative studies. Ideally, this will be performed with standardized, prospectively acquired clinical, imaging, exercise, electrocardiographic, and laboratory data. Such a large multicenter investigation would allow us to create an evidence-based consensus on the optimal timing and indications for PVR, as well as for refinement of surgical techniques. A collaborative endeavor such as that will help to overcome the relatively short duration of time that the procedure has been performed routinely (less than a decade in many institutions), the low rate of hard outcomes (eg, death, resuscitated cardiac arrest, sustained ventricular tachycardia), the reliance on surrogate outcomes of unclear clinical importance, and the ongoing evolution in treatment options. Such a prospective multicenter study would help generate hypotheses on optimal management that can then be tested in future randomized clinical trials.
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